{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:01:22Z","timestamp":1792065682636,"version":"4.4.0"},"reference-count":146,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,4,11]],"date-time":"2015-04-11T00:00:00Z","timestamp":1428710400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s00467-015-3076-8","type":"journal-article","created":{"date-parts":[[2015,4,9]],"date-time":"2015-04-09T18:46:25Z","timestamp":1428605185000},"page":"15-39","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":511,"title":["An international consensus approach to the management of atypical hemolytic uremic syndrome in children"],"prefix":"10.1007","volume":"31","author":[{"name":"for HUS International","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Loirat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Fakhouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Ariceta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesrin","family":"Besbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bitzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bjerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Coppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Emma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Karpman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig B","family":"Langman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Lapeyraque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Licht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Nester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Pecoraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C. A. J.","family":"van de Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Van de Walle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Vivarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Fr\u00e9meaux-Bacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,11]]},"reference":[{"key":"3076_CR1","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","volume":"5","author":"M Noris","year":"2010","unstructured":"Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5:1844\u20131859","journal-title":"Clin J Am Soc Nephrol"},{"key":"3076_CR2","doi-asserted-by":"crossref","first-page":"E1445","DOI":"10.1002\/humu.21256","volume":"31","author":"TK Maga","year":"2010","unstructured":"Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJ (2010) Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 31:E1445\u2013E1460","journal-title":"Hum Mutat"},{"key":"3076_CR3","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","volume":"8","author":"V Fremeaux-Bacchi","year":"2013","unstructured":"Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaim\u00e9 F, Dragon-Durey MA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Desch\u00eanes G, Lebranchu Y, Zuber J, Loirat C (2013) Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8:554\u2013562","journal-title":"Clin J Am Soc Nephrol"},{"key":"3076_CR4","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.semnephrol.2013.08.003","volume":"33","author":"D Kavanagh","year":"2013","unstructured":"Kavanagh D, Goodship TH, Richards A (2013) Atypical hemolytic uremic syndrome. Semin Nephrol 33:508\u2013530","journal-title":"Semin Nephrol"},{"key":"3076_CR5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/asheducation.V2012.1.617.3798924","volume":"2012","author":"CM Nester","year":"2012","unstructured":"Nester CM, Thomas CP (2012) Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated? Hematology 2012:617\u2013625","journal-title":"Hematology"},{"key":"3076_CR6","first-page":"27","volume":"33","author":"JM Campistol","year":"2013","unstructured":"Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa M, Griny\u00f3 JM, Praga M, Torra R, Vilalta R, Rodr\u00edguez de C\u00f3rdoba S (2013) An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 33:27\u201345","journal-title":"Nefrologia"},{"key":"3076_CR7","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1182\/blood-2013-11-516237","volume":"123","author":"SR Cataland","year":"2014","unstructured":"Cataland SR, Wu HM (2014) How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome. Blood 123:2478\u20132484","journal-title":"Blood"},{"key":"3076_CR8","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/bjh.12718","volume":"164","author":"M Scully","year":"2014","unstructured":"Scully M, Goodship T (2014) How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome. Br J Haematol 164:759\u2013766","journal-title":"Br J Haematol"},{"key":"3076_CR9","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng.2590","volume":"45","author":"M Lemaire","year":"2013","unstructured":"Lemaire M, Fr\u00e9meaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, Fakhouri F, Taque S, Nobili F, Martinez F, Ji W, Overton JD, Mane SM, N\u00fcrnberg G, Altm\u00fcller J, Thiele H, Morin D, Deschenes G, Baudouin V, Llanas B, Collard L, Majid MA, Simkova E, N\u00fcrnberg P, Rioux-Leclerc N, Moeckel GW, Gubler MC, Hwa J, Loirat C, Lifton RP (2013) Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 45:531\u2013536","journal-title":"Nat Genet"},{"key":"3076_CR10","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00467-008-0964-1","volume":"24","author":"G Ariceta","year":"2009","unstructured":"Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, Loirat C, Pecoraro C, Taylor CM, Van de Kar N, Vandewalle J, Zimmerhackl LB, European Paediatric Study Group for HUS (2009) Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 24:687\u2013696","journal-title":"Pediatr Nephrol"},{"key":"3076_CR11","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1007\/s00467-014-2817-4","volume":"29","author":"S Johnson","year":"2014","unstructured":"Johnson S, Stojanovic J, Ariceta G, Bitzan M, Besbas N, Karpman D, Frieling M, Landau D, Langman C, Licht C, Pecoraro C, Riedl M, Siomou E, Van de Kar N, Walle JV, Loirat C, Taylor CM (2014) An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome. Pediatr Nephrol 29:1967\u20131978","journal-title":"Pediatr Nephrol"},{"key":"3076_CR12","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2012.214","volume":"8","author":"J Zuber","year":"2012","unstructured":"Zuber J, Fakhouri F, Roumenina LT, Loirat C, Fr\u00e9meaux-Bacchi V, French Study Group for aHUS\/C3G (2012) Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 8:643\u2013657","journal-title":"Nat Rev Nephrol"},{"key":"3076_CR13","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, N\u00fcrnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368:2169\u20132181","journal-title":"N Engl J Med"},{"key":"3076_CR14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.molimm.2013.05.224","volume":"56","author":"EK Wong","year":"2013","unstructured":"Wong EK, Goodship TH, Kavanagh D (2013) Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol Immunol 56:199\u2013212","journal-title":"Mol Immunol"},{"key":"3076_CR15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/sj.ki.5001581","volume":"70","author":"N Besbas","year":"2006","unstructured":"Besbas N, Karpman D, Landau D, Loirat C, Proesmans W, Remuzzi G, Rizzoni G, Taylor CM, Van de Kar N, Zimmerhackl LB, Besbas N, Karpman D, Landau D, Loirat C, Proesmans W, Remuzzi G, Rizzoni G, Taylor CM, Van de Kar N, Zimmerhackl LB, European Paediatric Research Group for HUS (2006) A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 70:423\u2013431","journal-title":"Kidney Int"},{"key":"3076_CR16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1750-1172-6-60","volume":"6","author":"C Loirat","year":"2011","unstructured":"Loirat C, Fr\u00e9meaux-Bacchi V (2011) Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 6:60","journal-title":"Orphanet J Rare Dis"},{"key":"3076_CR17","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1182\/blood-2008-03-144691","volume":"112","author":"F Fakhouri","year":"2008","unstructured":"Fakhouri F, Jablonski M, Lepercq J, Blouin J, Benachi A, Hourmant M, Pirson Y, D\u00fcrrbach A, Gr\u00fcnfeld JP, Knebelmann B, Fr\u00e9meaux-Bacchi V (2008) Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome. Blood 112:4542\u20134545","journal-title":"Blood"},{"key":"3076_CR18","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1111\/j.1600-6143.2008.02297.x","volume":"8","author":"M Quintrec Le","year":"2008","unstructured":"Le Quintrec M, Lionet A, Kamar N, Karras A, Barbier S, Buchler M, Fakhouri F, Provost F, Fridman WH, Thervet E, Legendre C, Zuber J, Fr\u00e9meaux-Bacchi V (2008) Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant 8:1694\u20131701","journal-title":"Am J Transplant"},{"key":"3076_CR19","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1681\/ASN.2009070706","volume":"21","author":"F Fakhouri","year":"2010","unstructured":"Fakhouri F, Roumenina L, Provot F, Sall\u00e9e M, Caillard S, Couzi L, Essig M, Ribes D, Dragon-Durey MA, Bridoux F, Rondeau E, Fr\u00e9meaux-Bacchi V (2010) Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 21:859\u2013867","journal-title":"J Am Soc Nephrol"},{"key":"3076_CR20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/MOP.0b013e32835d7f2c","volume":"25","author":"JM Spinale","year":"2013","unstructured":"Spinale JM, Ruebner RL, Kaplan BS, Copelovitch L (2013) Update on Streptococcus pneumoniae associated hemolytic uremic syndrome. Curr Opin Pediatr 25:203\u2013208","journal-title":"Curr Opin Pediatr"},{"key":"3076_CR21","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1016\/j.lpm.2011.10.027","volume":"41","author":"H Yagi","year":"2012","unstructured":"Yagi H, Matsumoto M, Fujimura Y (2012) Paradigm shift of childhood thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency. Presse Med 41:e137\u2013e155","journal-title":"Presse Med"},{"key":"3076_CR22","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/MOP.0b013e32835e7888","volume":"25","author":"C Loirat","year":"2013","unstructured":"Loirat C, Coppo P, Veyradier A (2013) Thrombotic thrombocytopenic purpura in children. Curr Opin Pediatr 25:216\u2013224","journal-title":"Curr Opin Pediatr"},{"key":"3076_CR23","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1055\/s-0034-1376152","volume":"40","author":"WA Hassenpflug","year":"2014","unstructured":"Hassenpflug WA, Budde U, Schneppenheim S, Schneppenheim R (2014) Inherited thrombotic thrombocytopenic purpura in children. Semin Thromb Hemost 40:487\u2013492","journal-title":"Semin Thromb Hemost"},{"key":"3076_CR24","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/pbc.24612","volume":"60","author":"JA Reese","year":"2013","unstructured":"Reese JA, Muthurajah DS, Kremer Hovinga JA, Vesely SK, Terrell DR, George JN (2013) Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features. Pediatr Blood Cancer 60:1676\u20131682","journal-title":"Pediatr Blood Cancer"},{"key":"3076_CR25","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/blood-2014-01-550244","volume":"124","author":"M Hie","year":"2014","unstructured":"Hie M, Gay J, Galicier L, Prov\u00f4t F, Presne C, Poullin P, Bonmarchand G, Wynckel A, Benhamou Y, Vanhille P, Servais A, Bordessoule D, Coindre JP, Hamidou M, Vernant JP, Veyradier A, Coppo P, French Thrombotic Microangiopathies Reference Centre (2014) Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura. Blood 124:204\u2013210","journal-title":"Blood"},{"key":"3076_CR26","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/INF.0b013e31816a062f","volume":"27","author":"E Espi\u00e9","year":"2008","unstructured":"Espi\u00e9 E, Grimont F, Mariani-Kurkdjian P, Bouvet P, Haeghebaert S, Filliol I, Loirat C, Decludt B, Minh NN, Vaillant V, de Valk H (2008) Surveillance of hemolytic uremic syndrome in children less than 15\u00a0years of age, a system to monitor O157 and non-O157 Shiga toxin-producing Escherichia coli infections in France, 1996\u20132006. Pediatr Infect Dis J 27:595\u2013601","journal-title":"Pediatr Infect Dis J"},{"key":"3076_CR27","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/cid\/cis196","volume":"54","author":"A Rosales","year":"2012","unstructured":"Rosales A, Hofer J, Zimmerhackl LB, Jungraithmayr TC, Riedl M, Giner T, Strasak A, Orth-H\u00f6ller D, W\u00fcrzner R, Karch H, German-Austrian HUS Study Group (2012) Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae. Clin Infect Dis 54:1413\u20131421","journal-title":"Clin Infect Dis"},{"key":"3076_CR28","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00467-012-2383-6","volume":"28","author":"JM Spinale","year":"2013","unstructured":"Spinale JM, Ruebner RL, Copelovitch L, Kaplan BS (2013) Long-term outcomes of Shiga toxin hemolytic uremic syndrome. Pediatr Nephrol 28:2097\u20132105","journal-title":"Pediatr Nephrol"},{"key":"3076_CR29","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00467-007-0604-1","volume":"22","author":"AP Sharma","year":"2007","unstructured":"Sharma AP, Greenberg CR, Prasad AN, Prasad C (2007) Hemolytic uremic syndrome (HUS) secondary to cobalamin C (cblC) disorder. Pediatr Nephrol 22:2097\u20132103","journal-title":"Pediatr Nephrol"},{"key":"3076_CR30","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s00467-012-2152-6","volume":"27","author":"F Menni","year":"2012","unstructured":"Menni F, Testa S, Guez S, Chiarelli G, Alberti L, Esposito S (2012) Neonatal atypical hemolytic uremic syndrome due to methylmalonic aciduria and homocystinuria. Pediatr Nephrol 27:1401\u20131405","journal-title":"Pediatr Nephrol"},{"key":"3076_CR31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.ajkd.2013.08.031","volume":"63","author":"E Cornec-Le Gall","year":"2013","unstructured":"Cornec-Le Gall E, Delmas Y, De Parscau L, Doucet L, Ogier H, Benoist JF, Fremeaux-Bacchi V, Le Meur Y (2013) Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency. Am J Kidney Dis 63:119\u2013123","journal-title":"Am J Kidney Dis"},{"key":"3076_CR32","doi-asserted-by":"crossref","first-page":"e540","DOI":"10.1542\/peds.2012-2581","volume":"132","author":"M K\u00f6mhoff","year":"2013","unstructured":"K\u00f6mhoff M, Roofthooft MT, Westra D, Teertstra TK, Losito A, van de Kar NC, Berger RM (2013) Combined pulmonary hypertension and renal thrombotic microangiopathy in cobalamin C deficiency. Pediatrics 132:e540\u2013e544","journal-title":"Pediatrics"},{"key":"3076_CR33","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s10545-014-9687-6","volume":"37","author":"S Fischer","year":"2014","unstructured":"Fischer S, Huemer M, Baumgartner M, Deodato F, Ballhausen D, Boneh A, Burlina AB, Cerone R, Garcia P, G\u00f6k\u00e7ay G, Gr\u00fcnewald S, H\u00e4berle J, Jaeken J, Ketteridge D, Lindner M, Mandel H, Martinelli D, Martins EG, Schwab KO, Gruenert SC, Schwahn BC, Sztriha L, Tomaske M, Trefz F, Vilarinho L, Rosenblatt DS, Fowler B, Dionisi-Vici C (2014) Clinical presentation and outcome in a series of 88 patients with the cblC defect. J Inherit Metab Dis 37:831\u2013840","journal-title":"J Inherit Metab Dis"},{"key":"3076_CR34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13023-014-0161-1","volume":"9","author":"M Huemer","year":"2014","unstructured":"Huemer M, Scholl-B\u00fcrgi S, Hadaya K, Kern I, Beer R, Seppi K, Fowler B, Baumgartner MR, Karall D (2014) Three new cases of late-onset cblC defect and review of the literature illustrating when to consider inborn errors of metabolism beyond infancy. Orphanet J Rare Dis 9:161","journal-title":"Orphanet J Rare Dis"},{"key":"3076_CR35","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/bjh.12202","volume":"161","author":"R Peffault de Latour","year":"2013","unstructured":"Peffault de Latour R, Xhaard A, Fremeaux-Bacchi V, Coppo P, Fischer AM, Helley D, Soci\u00e9 G (2013) Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy. Br J Haematol 161:279\u2013280","journal-title":"Br J Haematol"},{"key":"3076_CR36","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2013-05-501445","volume":"122","author":"S Jodele","year":"2013","unstructured":"Jodele S, Licht C, Goebel J, Dixon BP, Zhang K, Sivakumaran TA, Davies SM, Pluthero FG, Lu L, Laskin BL (2013) Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood 122:2003\u20132007","journal-title":"Blood"},{"key":"3076_CR37","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbmt.2013.12.565","volume":"20","author":"S Jodele","year":"2014","unstructured":"Jodele S, Fukuda T, Vinks A, Mizuno K, Laskin BL, Goebel J, Dixon BP, Teusink A, Pluthero FG, Lu L, Licht C, Davies SM (2014) Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant 20:518\u2013525","journal-title":"Biol Blood Marrow Transplant"},{"key":"3076_CR38","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1093\/ndt\/gft198","volume":"28","author":"A Szil\u00e1gyi","year":"2013","unstructured":"Szil\u00e1gyi A, Kiss N, Bereczki C, T\u00e1losi G, R\u00e1cz K, T\u00fari S, Gy\u00f6rke Z, Simon E, Horv\u00e1th E, Kelen K, Reusz GS, Szab\u00f3 AJ, Tulassay T, Proh\u00e1szka Z (2013) The role of complement in Streptococcus pneumoniae-associated haemolytic uraemic syndrome. Nephrol Dial Transplant 28:2237\u20132245","journal-title":"Nephrol Dial Transplant"},{"key":"3076_CR39","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.mehy.2013.05.030","volume":"81","author":"RD Gilbert","year":"2013","unstructured":"Gilbert RD, Nagra A, Haq MR (2013) Does dysregulated complement activation contribute to haemolytic uraemic syndrome secondary to Streptococcus pneumoniae? Med Hypotheses 81:400\u2013403","journal-title":"Med Hypotheses"},{"key":"3076_CR40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2141.2005.05420.x","volume":"129","author":"K Kokame","year":"2005","unstructured":"Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T (2005) FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 129:93\u2013100","journal-title":"Br J Haematol"},{"key":"3076_CR41","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1160\/TH12-08-0565","volume":"109","author":"I Mackie","year":"2013","unstructured":"Mackie I, Langley K, Chitolie A, Liesner R, Scully M, Machin S, Peyvandi F (2013) Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies. Thromb Haemost 109:488\u2013496","journal-title":"Thromb Haemost"},{"key":"3076_CR42","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1160\/TH13-05-0393","volume":"110","author":"S Thouzeau","year":"2013","unstructured":"Thouzeau S, Capdenat S, St\u00e9panian A, Coppo P, Veyradier A (2013) Evaluation of a commercial assay for ADAMTS13 activity measurement. Thromb Haemost 110:852\u2013853","journal-title":"Thromb Haemost"},{"key":"3076_CR43","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1681\/ASN.2005010086","volume":"16","author":"M Noris","year":"2005","unstructured":"Noris M, Bucchioni S, Galbusera M, Donadelli R, Bresin E, Castelletti F, Caprioli J, Brioschi S, Scheiflinger F, Remuzzi G, Noris M, Bucchioni S, Galbusera M, Donadelli R, Bresin E, Castelletti F, Caprioli J, Brioschi S, Scheiflinger F, Remuzzi G, International Registry of Recurrent and Familial HUS\/TTP (2005) Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. J Am Soc Nephrol 16:1177\u20131183","journal-title":"J Am Soc Nephrol"},{"key":"3076_CR44","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s00467-013-2561-1","volume":"29","author":"LS Keir","year":"2014","unstructured":"Keir LS, Saleem MA (2014) Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome. Pediatr Nephrol 29:1895\u20131902","journal-title":"Pediatr Nephrol"},{"key":"3076_CR45","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.molimm.2013.11.009","volume":"58","author":"K Poolpol","year":"2014","unstructured":"Poolpol K, Orth-H\u00f6ller D, Speth C, Zipfel PF, Skerka C, de C\u00f3rdoba SR, Brockmeyer J, Bielaszewska M, W\u00fcrzner R (2014) Interaction of Shiga toxin 2 with complement regulators of the factor H protein family. Mol Immunol 58:77\u201384","journal-title":"Mol Immunol"},{"key":"3076_CR46","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1053\/j.ajkd.2004.12.004","volume":"45","author":"V Guigonis","year":"2005","unstructured":"Guigonis V, Fr\u00e9meaux-Bacchi V, Giraudier S, Favier R, Borderie D, Massy Z, Mougenot B, Rosenblatt DS, Desch\u00eanes G (2005) Late-onset thrombocytic microangiopathy caused by cblC disease: association with a factor H mutation. Am J Kidney Dis 45:588\u2013595","journal-title":"Am J Kidney Dis"},{"key":"3076_CR47","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1007\/s00467-010-1609-8","volume":"25","author":"AH Bouts","year":"2010","unstructured":"Bouts AH, Roofthooft MT, Salomons GS (2010) CD46-associated atypical hemolytic uremic syndrome with uncommon course caused by cblC deficiency. Pediatr Nephrol 25:2547\u20132548","journal-title":"Pediatr Nephrol"},{"key":"3076_CR48","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/j.lpm.2011.11.013","volume":"41","author":"C Loirat","year":"2012","unstructured":"Loirat C, Saland J, Bitzan M (2012) Management of hemolytic uremic syndrome. Presse Med 41:e115\u2013e135","journal-title":"Presse Med"},{"key":"3076_CR49","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1182\/blood-2007-08-106153","volume":"111","author":"AL St\u00e5hl","year":"2008","unstructured":"St\u00e5hl AL, Vaziri-Sani F, Heinen S, Kristoffersson AC, Gydell KH, Raafat R, Gutierrez A, Beringer O, Zipfel PF, Karpman D (2008) Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood 111:5307\u20135315","journal-title":"Blood"},{"key":"3076_CR50","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2010030315","volume":"21","author":"MA Dragon-Durey","year":"2010","unstructured":"Dragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, Andr\u00e9 JL, Takagi N, Cheong HI, Hari P, Le Quintrec M, Niaudet P, Loirat C, Fridman WH, Fr\u00e9meaux-Bacchi V (2010) Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 21:2180\u20132187","journal-title":"J Am Soc Nephrol"},{"key":"3076_CR51","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2215\/CJN.01260212","volume":"8","author":"J Hofer","year":"2013","unstructured":"Hofer J, Janecke AR, Zimmerhackl LB, Riedl M, Rosales A, Giner T, Cortina G, Haindl CJ, Petzelberger B, Pawlik M, Jeller V, Vester U, Gadner B, van Husen M, Moritz ML, W\u00fcrzner R, Jungraithmayr T, German-Austrian HUS Study Group (2013) Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 8:407\u2013415","journal-title":"Clin J Am Soc Nephrol"},{"key":"3076_CR52","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/ki.2013.373","volume":"85","author":"A Sinha","year":"2014","unstructured":"Sinha A, Gulati A, Saini S, Blanc C, Gupta A, Gurjar BS, Saini H, Kotresh ST, Ali U, Bhatia D, Ohri A, Kumar M, Agarwal I, Gulati S, Anand K, Vijayakumar M, Sinha R, Sethi S, Salmona M, George A, Bal V, Singh G, Dinda AK, Hari P, Rath S, Dragon-Durey MA, Bagga A (2014) Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int 85:1151\u20131160","journal-title":"Kidney Int"},{"key":"3076_CR53","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/ki.2013.447","volume":"85","author":"C Loirat","year":"2014","unstructured":"Loirat C, Fremeaux-Bacchi V (2014) Anti-factor H autoantibody-associated haemolytic uremic syndrome: the earlier diagnosed and treated, the better. Kidney Int 85:1019\u20131022","journal-title":"Kidney Int"},{"key":"3076_CR54","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1055\/s-0034-1375297","volume":"40","author":"J Hofer","year":"2014","unstructured":"Hofer J, Giner T, J\u00f3zsi M (2014) Complement factor h-antibody-associated hemolytic uremic syndrome: pathogenesis, clinical presentation, and treatment. Semin Thromb Hemost 40:431\u2013443","journal-title":"Semin Thromb Hemost"},{"key":"3076_CR55","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1542\/peds.2012-0903","volume":"131","author":"M Malina","year":"2013","unstructured":"Malina M, Gulati A, Bagga A, Majid MA, Simkova E, Schaefer F (2013) Peripheral gangrene in children with atypical hemolytic uremic syndrome. Pediatrics 131:e331\u2013e335","journal-title":"Pediatrics"},{"key":"3076_CR56","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1681\/ASN.2013080886","volume":"25","author":"R Westland","year":"2014","unstructured":"Westland R, Bodria M, Carrea A, Lata S, Scolari F, Fremeaux-Bacchi V, D'Agati VD, Lifton RP, Gharavi AG, Ghiggeri GM, Sanna-Cherchi S (2014) Phenotypic expansion of DGKE-associated diseases. J Am Soc Nephrol 25:1408\u20131414","journal-title":"J Am Soc Nephrol"},{"key":"3076_CR57","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2215\/CJN.01640214","volume":"9","author":"D S\u00e1nchez Chinchilla","year":"2014","unstructured":"S\u00e1nchez Chinchilla D, Pinto S, Hoppe B, Adragna M, Lopez L, Justa Roldan ML, Pe\u00f1a A, Lopez Trascasa M, S\u00e1nchez-Corral P, Rodr\u00edguez de C\u00f3rdoba S (2014) Complement mutations in diacylglycerol kinase-\u03b5-associated atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 9:1611\u20131619","journal-title":"Clin J Am Soc Nephrol"},{"key":"3076_CR58","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1681\/ASN.2005101051","volume":"17","author":"V Fremeaux-Bacchi","year":"2006","unstructured":"Fremeaux-Bacchi V, Moulton EA, Kavanagh D, Dragon-Durey MA, Blouin J, Caudy A, Arzouk N, Cleper R, Francois M, Guest G, Pourrat J, Seligman R, Fridman WH, Loirat C, Atkinson JP (2006) Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol 17:2017\u20132025","journal-title":"J Am Soc Nephrol"},{"key":"3076_CR59","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1681\/ASN.2012090884","volume":"24","author":"E Bresin","year":"2013","unstructured":"Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S, Pinto S, Goodship TH, Alberti M, Ribes D, Valoti E, Remuzzi G, Noris M, European Working Party on Complement Genetics in Renal Diseases (2013) Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol 24:475\u2013486","journal-title":"J Am Soc Nephrol"},{"key":"3076_CR60","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1681\/ASN.2013050453","volume":"25","author":"F Bu","year":"2014","unstructured":"Bu F, Maga T, Meyer NC, Wang K, Thomas CP, Nester CM, Smith RJ (2014) Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol 25:55\u201364","journal-title":"J Am Soc Nephrol"},{"key":"3076_CR61","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1182\/blood-2013-03-492421","volume":"22","author":"S Feng","year":"2013","unstructured":"Feng S, Eyler SJ, Zhang Y, Maga T, Nester CM, Kroll MH, Smith RJ, Afshar-Kharghan V (2013) Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome. Blood 22:1487\u20131493","journal-title":"Blood"},{"key":"3076_CR62","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2009-05-221549","volume":"115","author":"I Moore","year":"2010","unstructured":"Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, Schmidt CQ, Staniforth SJ, Holmes LV, Ward R, Morgan L, Goodship TH, Marchbank KJ (2010) Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 115:379\u2013387","journal-title":"Blood"},{"key":"3076_CR63","doi-asserted-by":"crossref","first-page":"e60352","DOI":"10.1371\/journal.pone.0060352","volume":"8","author":"LV Holmes","year":"2013","unstructured":"Holmes LV, Strain L, Staniforth SJ, Moore I, Marchbank K, Kavanagh D, Goodship JA, Cordell HJ, Goodship TH (2013) Determining the population frequency of the CFHR3\/CFHR1 deletion at 1q32. PLoS One 8:e60352","journal-title":"PLoS One"},{"key":"3076_CR64","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/ng.2622","volume":"45","author":"SE Quaggin","year":"2013","unstructured":"Quaggin SE (2013) DGKE and atypical HUS. Nat Genet 45:475\u2013476","journal-title":"Nat Genet"},{"key":"3076_CR65","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00467-012-2131-y","volume":"27","author":"LM Geerdink","year":"2012","unstructured":"Geerdink LM, Westra D, van Wijk JA, Dorresteijn EM, Lilien MR, Davin JC, K\u00f6mhoff M, Van Hoeck K, van der Vlugt A, van den Heuvel LP, van de Kar NC (2012) Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol 27:1283\u20131291","journal-title":"Pediatr Nephrol"},{"key":"3076_CR66","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2013-12-547067","volume":"123","author":"SR Cataland","year":"2014","unstructured":"Cataland SR, Holers VM, Geyer S, Yang S, Wu HM (2014) Biomarkers of the alternative pathway and terminal complement activity at presentation confirms the clinical diagnosis of aHUS and differentiates aHUS from TTP. Blood 123:3733\u20133738","journal-title":"Blood"},{"key":"3076_CR67","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","volume":"124","author":"M Noris","year":"2014","unstructured":"Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E, Tripodo C, Bettoni S, Donadelli R, Valoti E, Tedesco F, Amore A, Coppo R, Ruggenenti P, Gotti E, Remuzzi G (2014) Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 124:1715\u20131726","journal-title":"Blood"},{"key":"3076_CR68","author":"EB Volokhina","year":"2014","unstructured":"Volokhina EB, Westra D, van der Velden TJ, van de Kar NC, Mollnes TE, van den Heuvel LP (2014) Complement activation patterns in atypical hemolytic uremic syndrome during acute phase and in remission. Clin Exp Immunol. doi: 10.1111\/cei.12426","journal-title":"Clin Exp Immunol"},{"key":"3076_CR69","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.imbio.2013.06.004","volume":"219","author":"R Watson","year":"2014","unstructured":"Watson R, Lindner S, Bordereau P, Hunze EM, Tak F, Ngo S, Zipfel PF, Skerka C, Dragon-Durey MA, Marchbank KJ (2014) Standardisation of the factor H autoantibody assay. Immunobiology 219:9\u201316","journal-title":"Immunobiology"},{"key":"3076_CR70","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/ajt.12077","volume":"13","author":"M Quintrec Le","year":"2013","unstructured":"Le Quintrec M, Zuber J, Moulin B, Kamar N, Jablonski M, Lionet A, Chatelet V, Mousson C, Mourad G, Bridoux F, Cassuto E, Loirat C, Rondeau E, Delahousse M, Fr\u00e9meaux-Bacchi V (2013) Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 13:663\u2013675","journal-title":"Am J Transplant"},{"key":"3076_CR71","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1111\/j.1600-6143.2012.04252.x","volume":"12","author":"J Zuber","year":"2012","unstructured":"Zuber J, Le Quintrec M, Krid S, Bertoye C, Gueutin V, Lahoche A, Heyne N, Ardissino G, Chatelet V, No\u00ebl LH, Hourmant M, Niaudet P, Fr\u00e9meaux-Bacchi V, Rondeau E, Legendre C, Loirat C, French Study Group for Atypical HUS (2012) Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 12:3337\u20133354","journal-title":"Am J Transplant"},{"key":"3076_CR72","doi-asserted-by":"crossref","first-page":"E134","DOI":"10.1111\/petr.12273","volume":"18","author":"P Khandelwal","year":"2014","unstructured":"Khandelwal P, Sinha A, Hari P, Bansal VK, Dinda AK, Bagga A (2014) Outcomes of renal transplant in patients with anti-complement factor H antibody-associated hemolytic uremic syndrome. Pediatr Transplant 18:E134\u2013E139","journal-title":"Pediatr Transplant"},{"key":"3076_CR73","doi-asserted-by":"crossref","first-page":"E177","DOI":"10.1111\/petr.12151","volume":"17","author":"S Sinibaldi","year":"2013","unstructured":"Sinibaldi S, Guzzo I, Piras R, Bresin E, Emma F, Dello Strologo L (2013) Post-transplant recurrence of atypical hemolytic uremic syndrome in a patient with thrombomodulin mutation. Pediatr Transplant 17:E177\u2013E181","journal-title":"Pediatr Transplant"},{"key":"3076_CR74","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1681\/ASN.2008080906","volume":"20","author":"JM Saland","year":"2009","unstructured":"Saland JM, Ruggenenti P, Remuzzi G, Consensus Study Group (2009) Liver\u2013kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol 20:940\u2013949","journal-title":"J Am Soc Nephrol"},{"key":"3076_CR75","unstructured":"European Medicines Agency. Soliris (eculizumab): EU summary of product characteristics.Mar14 http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR__Product_Information\/ human\/000791\/WC500054208.pdf"},{"key":"3076_CR76","unstructured":"Alexion Pharmaceuticals Inc. Soliris_ (eculizumab): US prescribing information.4\/2014. http:\/\/www.accessdata.fda.gov\/drugsatfda docs\/label\/2014\/125166s368s380lbl.pdf"},{"key":"3076_CR77","author":"C Licht","year":"2015","unstructured":"Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen D, Delmas Y, Douglas K, Furman R, Gaber O, Goodship T, Herthelius M, Hourmant M, Legendre C, Remuzzi G, Sheerin N, Trivelli A, Loirat C (2015) Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome: 2-year results from extensions of phase 2 studies. Kidney Int. doi: 10.1038\/ki.2014.423","journal-title":"Kidney Int"},{"key":"3076_CR78","first-page":"278","volume":"13","author":"C Legendre","year":"2013","unstructured":"Legendre C, Greenbaum L, Sheerin N, Cohen D, Gaber A, Eitner F, Delmas Y, Furman R, Feldkamp T, Fouque D, Bedrosian C, Loirat C (2013) Eculizumab efficacy in aHUS patients with progressing TMA, with or without prior renal transplant [Abstract]. Am J Transplant 13:278\u2013279","journal-title":"Am J Transplant"},{"key":"3076_CR79","first-page":"821A","volume":"24","author":"LA Greenbaum","year":"2013","unstructured":"Greenbaum LA, Fila M, Tsimaratos M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, Van De Kar N, Van De Walle J, Ogawa M, Bedrosian CL, Licht C (2013) Eculizumab inhibits thrombotic microangiopathy and improves renal function in pediatric atypical hemolytic uremic syndrome patients [Abstract]. J Am Soc Nephrol 24:821A\u2013822A","journal-title":"J Am Soc Nephrol"},{"key":"3076_CR80","first-page":"751A","volume":"25","author":"F Fakhouri","year":"2014","unstructured":"Fakhouri F, Hourmant M, Campistol Plana JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provot F, Rondeau E, Ruggenenti PL, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM (2014) Eculizumab inhibits thrombotic microangiopathy, and improves renal function in adult atypical hemolytic uremic syndrome patients: 1-Year Update [Abstract]. J Am Soc Nephrol 25:751A","journal-title":"J Am Soc Nephrol"},{"key":"3076_CR81","first-page":"754","volume":"25","author":"C Loirat","year":"2014","unstructured":"Loirat C, Legendre CM, Ogawa M, Bedrosian CL, Kincaid J, Fakhouri F (2014) Safety and efficacy of eculizumab in adult aHUS patients, with or without a history of renal transplant [Abstract]. J Am Soc Nephrol 25:754","journal-title":"J Am Soc Nephrol"},{"key":"3076_CR82","doi-asserted-by":"crossref","first-page":"e003573","DOI":"10.1136\/bmjopen-2013-003573","volume":"3","author":"J Rathbone","year":"2013","unstructured":"Rathbone J, Kaltenthaler E, Richards A, Tappenden P, Bessey A, Cantrell A (2013) A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open 3:e003573","journal-title":"BMJ Open"},{"key":"3076_CR83","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1007\/s00467-012-2276-8","volume":"27","author":"R Vilalta","year":"2012","unstructured":"Vilalta R, Lara E, Madrid A, Chocron S, Mu\u00f1oz M, Casquero A, Nieto J (2012) Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome. Pediatr Nephrol 27:2323\u20132326","journal-title":"Pediatr Nephrol"},{"key":"3076_CR84","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1007\/s00467-012-2283-9","volume":"27","author":"FS Cayci","year":"2012","unstructured":"Cayci FS, Cakar N, Hancer VS, Uncu N, Acar B, Gur G (2012) Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation. Pediatr Nephrol 27:2327\u20132331","journal-title":"Pediatr Nephrol"},{"key":"3076_CR85","doi-asserted-by":"crossref","first-page":"e1385","DOI":"10.1542\/peds.2011-1685","volume":"130","author":"M Giordano","year":"2012","unstructured":"Giordano M, Castellano G, Messina G, Divella C, Bellantuono R, Puteo F, Colella V, Depalo T, Gesualdo L (2012) Preservation of renal function in atypical hemolytic uremic syndrome by eculizumab: a case report. Pediatrics 130:e1385\u2013e1388","journal-title":"Pediatrics"},{"key":"3076_CR86","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00467-012-2296-4","volume":"28","author":"N Besbas","year":"2013","unstructured":"Besbas N, Gulhan B, Karpman D, Topaloglu R, Duzova A, Korkmaz E, Ozaltin F (2013) Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab. Pediatr Nephrol 28:155\u2013158","journal-title":"Pediatr Nephrol"},{"key":"3076_CR87","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00467-013-2416-9","volume":"28","author":"K Gulleroglu","year":"2013","unstructured":"Gulleroglu K, Fidan K, Han\u00e7er VS, Bayrakci U, Baskin E, Soylemezoglu O (2013) Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab. Pediatr Nephrol 28:827\u2013830","journal-title":"Pediatr Nephrol"},{"key":"3076_CR88","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s00467-013-2492-x","volume":"28","author":"RD Gilbert","year":"2013","unstructured":"Gilbert RD, Fowler DJ, Angus E, Hardy SA, Stanley L, Goodship TH (2013) Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor B. Pediatr Nephrol 28:1315\u20131318","journal-title":"Pediatr Nephrol"},{"key":"3076_CR89","doi-asserted-by":"crossref","first-page":"237","DOI":"10.5935\/0101-2800.20130037","volume":"35","author":"MH Vaisbich","year":"2013","unstructured":"Vaisbich MH, Henriques Ldos S, Watanabe A, Pereira LM, Metran CC, Malheiros DA, Modanez F, Silva JD, Vieira S, Macedo AC, Massarope B, Furusawa EA, Schvartsman BG (2013) Eculizumab for the treatment of atypical hemolytic uremic syndrome: case report and revision of the literature. J Bras Nefrol 35:237\u2013241","journal-title":"J Bras Nefrol"},{"key":"3076_CR90","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00467-013-2709-z","volume":"29","author":"H Hu","year":"2013","unstructured":"Hu H, Nagra A, Haq MR, Gilbert RD (2013) Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement. Pediatr Nephrol 29:1103\u20131106","journal-title":"Pediatr Nephrol"},{"key":"3076_CR91","doi-asserted-by":"crossref","first-page":"e1759","DOI":"10.1542\/peds.2013-1787","volume":"133","author":"M Christmann","year":"2014","unstructured":"Christmann M, Hansen M, Bergmann C, Schwabe D, Brand J, Schneider W (2014) Eculizumab as first-line therapy for atypical hemolytic uremic syndrome. Pediatrics 133:e1759\u2013e1763","journal-title":"Pediatrics"},{"key":"3076_CR92","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1007\/s00467-014-2933-1","volume":"29","author":"K Michaux","year":"2014","unstructured":"Michaux K, Bacchetta J, Javouhey E, Cochat P, Fr\u00e9maux-Bacchi V, Sellier-Leclerc AL (2014) Eculizumab in neonatal hemolytic uremic syndrome with homozygous factor H deficiency. Pediatr Nephrol 29:2415\u20132419","journal-title":"Pediatr Nephrol"},{"key":"3076_CR93","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/j.ajkd.2013.07.011","volume":"63","author":"F Fakhouri","year":"2014","unstructured":"Fakhouri F, Delmas Y, Provot F, Barbet C, Karras A, Makdassi R, Courivaud C, Rifard K, Servais A, Allard C, Besson V, Cousin M, Ch\u00e2telet V, Goujon JM, Coindre JP, Laurent G, Loirat C, Fr\u00e9meaux-Bacchi V (2014) Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases. Am J Kidney Dis 63:40\u201348","journal-title":"Am J Kidney Dis"},{"key":"3076_CR94","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1159\/000337954","volume":"35","author":"KS Hodgkins","year":"2012","unstructured":"Hodgkins KS, Bobrowski AE, Lane JC, Langman CB (2012) Clinical grand rounds: atypical hemolytic uremic syndrome. Am J Nephrol 35:394\u2013394","journal-title":"Am J Nephrol"},{"key":"3076_CR95","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1111\/j.1432-2277.2012.01497.x","volume":"25","author":"N Alachkar","year":"2012","unstructured":"Alachkar N, Bagnasco SM, Montgomery RA (2012) Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft. Transpl Int 25:e93\u2013e95","journal-title":"Transpl Int"},{"key":"3076_CR96","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1097\/01.TP.0000435705.63428.1f","volume":"96","author":"S Reuter","year":"2013","unstructured":"Reuter S, Heitplatz B, Pavenst\u00e4dt H, Suwelack B (2013) Successful long-term treatment of TMA with eculizumab in a transplanted patient with atypical hemolytic uremic syndrome due to MCP mutation. Transplantation 96:e74\u2013e76","journal-title":"Transplantation"},{"key":"3076_CR97","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.trre.2013.07.003","volume":"27","author":"J Zuber","year":"2013","unstructured":"Zuber J, Le Quintrec M, Morris H, Fr\u00e9meaux-Bacchi V, Loirat C, Legendre C (2013) Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. Transplant Rev (Orlando) 27:117\u2013125","journal-title":"Transplant Rev (Orlando)"},{"key":"3076_CR98","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1016\/j.transproceed.2012.07.141","volume":"44","author":"L Xie","year":"2012","unstructured":"Xie L, Nester CM, Reed AI, Zhang Y, Smith RJ, Thomas CP (2012) Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report. Transplant Proc 44:3037\u20133040","journal-title":"Transplant Proc"},{"key":"3076_CR99","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1097\/TP.0b013e31829d388d","volume":"96","author":"MB Pelicano","year":"2013","unstructured":"Pelicano MB, de C\u00f3rdoba SR, Diekmann F, Saiz M, Herrero S, Oppenheimer F, Campistol JM (2013) Anti-C5 as prophylactic therapy in atypical hemolytic uremic syndrome in living-related kidney transplantation. Transplantation 96:e26\u2013e29","journal-title":"Transplantation"},{"key":"3076_CR100","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00467-013-2591-8","volume":"29","author":"E Rom\u00e1n-Ortiz","year":"2014","unstructured":"Rom\u00e1n-Ortiz E, Mendizabal Oteiza S, Pinto S, L\u00f3pez-Trascasa M, S\u00e1nchez-Corral P, Rodr\u00edguez de Cordoba S (2014) Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH\/CFHR1 hybrid gene. Pediatr Nephrol 29:149\u2013153","journal-title":"Pediatr Nephrol"},{"key":"3076_CR101","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1093\/ndt\/gft340","volume":"28","author":"ZD B\u00e9k\u00e1ssy","year":"2013","unstructured":"B\u00e9k\u00e1ssy ZD, Kristoffersson AC, Cronqvist M, Roumenina LT, Rybkine T, Vergoz L, Hue C, Fremeaux-Bacchi V, Karpman D (2013) Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions. Nephrol Dial Transplant 28:2899\u20132907","journal-title":"Nephrol Dial Transplant"},{"key":"3076_CR102","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJM200104053441406","volume":"344","author":"MJ Walport","year":"2001","unstructured":"Walport MJ (2001) Complement. First of two parts. N Engl J Med 344:1058\u20131066","journal-title":"N Engl J Med"},{"key":"3076_CR103","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4161\/hv.27051","volume":"10","author":"TM Nolan","year":"2013","unstructured":"Nolan TM, Nissen MD, Naz A, Shepard J, Bedell L, Hohenboken M, Odrljin T, Dull PM (2013) Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2\u00a0months of age. Hum Vaccin Immunother 10:280\u2013289","journal-title":"Hum Vaccin Immunother"},{"key":"3076_CR104","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.vaccine.2013.12.034","volume":"32","author":"A Abdelnour","year":"2014","unstructured":"Abdelnour A, Silas PE, Lamas MR, Arag\u00f3n CF, Chiu NC, Chiu CH, Acu\u00f1a TH, Castrej\u00f3n Tde L, Izu A, Odrljin T, Smolenov I, Hohenboken M, Dull PM (2014) Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants. Vaccine 32:965\u2013972","journal-title":"Vaccine"},{"key":"3076_CR105","doi-asserted-by":"crossref","first-page":"E246","DOI":"10.1111\/j.1399-3046.2011.01585.x","volume":"16","author":"M Zlamy","year":"2012","unstructured":"Zlamy M, Hofer J, Elias J, Vogel U, Frosch M, Jungraithmayr T, Zimmerhackl LB, Prelog M (2012) Immunogenicity of meningococcus C vaccination in a patient with atypical hemolytic uremic syndrome (aHUS) on eculizumab therapy. Pediatr Transplant 16:E246\u2013E250","journal-title":"Pediatr Transplant"},{"key":"3076_CR106","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/ajt.12032","volume":"13","author":"GH Struijk","year":"2013","unstructured":"Struijk GH, Bouts AH, Rijkers GT, Kuin EA, ten Berge IJ, Bemelman FJ (2013) Meningococcal sepsis complicating eculizumab treatment despite prior vaccination. Am J Transplant 13:819\u2013820","journal-title":"Am J Transplant"},{"key":"3076_CR107","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.12347","volume":"162","author":"P Hillmen","year":"2013","unstructured":"Hillmen P, Muus P, R\u00f6th A, Elebute MO, Risitano AM, Schrezenmeier H, Szer J, Browne P, Maciejewski JP, Schubert J, Urbano-Ispizua A, de Castro C, Soci\u00e9 G, Brodsky RA (2013) Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 162:62\u201373","journal-title":"Br J Haematol"},{"key":"3076_CR108","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00467-013-2558-9","volume":"29","author":"G Sana","year":"2014","unstructured":"Sana G, Dragon-Durey MA, Charbit M, Bouchireb K, Rousset-Rouvi\u00e8re C, B\u00e9rard E, Salomon R, Fr\u00e9meaux-Bacchi V, Niaudet P, Boyer O (2014) Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses. Pediatr Nephrol 29:75\u201383","journal-title":"Pediatr Nephrol"},{"key":"3076_CR109","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00467-013-2654-x","volume":"29","author":"D Noone","year":"2014","unstructured":"Noone D, Waters A, Pluthero FG, Geary DF, Kirschfink M, Zipfel PF, Licht C (2014) Successful treatment of DEAP-HUS with eculizumab. Pediatr Nephrol 29:841\u2013851","journal-title":"Pediatr Nephrol"},{"key":"3076_CR110","doi-asserted-by":"crossref","first-page":"e1764","DOI":"10.1542\/peds.2013-1594","volume":"133","author":"B Diamante Chiodini","year":"2014","unstructured":"Diamante Chiodini B, Davin JC, Corazza F, Khaldi K, Dahan K, Ismaili K, Adams B (2014) Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome. Pediatrics 133:e1764\u2013e1768","journal-title":"Pediatrics"},{"key":"3076_CR111","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3109\/0886022X.2014.917574","volume":"36","author":"H Green","year":"2014","unstructured":"Green H, Harari E, Davidovits M, Blickstein D, Grossman A, Gafter U, Gafter-Gvili A (2014) Atypical HUS due to factor H antibodies in an adult patient successfully treated with eculizumab. Ren Fail 36:1119\u20131121","journal-title":"Ren Fail"},{"key":"3076_CR112","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1681\/ASN.2006080811","volume":"18","author":"AL Sellier-Leclerc","year":"2007","unstructured":"Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, Boudailliez B, Bouissou F, Deschenes G, Gie S, Tsimaratos M, Fischbach M, Morin D, Nivet H, Alberti C, Loirat C, French Society of Pediatric Nephrology (2007) Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 18:2392\u20132400","journal-title":"J Am Soc Nephrol"},{"key":"3076_CR113","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1538-7836.2012.04674.x","volume":"10","author":"M R\u00e9ti","year":"2012","unstructured":"R\u00e9ti M, Farkas P, Csuka D, R\u00e1zs\u00f3 K, Schlammadinger \u00c1, Udvardy ML, Mad\u00e1ch K, Domj\u00e1n G, Bereczki C, Reusz GS, Szab\u00f3 AJ, Proh\u00e1szka Z (2012) Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost 10:791\u2013798","journal-title":"J Thromb Haemost"},{"key":"3076_CR114","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrneph.2012.195","volume":"8","author":"M Noris","year":"2012","unstructured":"Noris M, Mescia F, Remuzzi G (2012) STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 8:622\u2013633","journal-title":"Nat Rev Nephrol"},{"key":"3076_CR115","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1111\/jth.12369","volume":"11","author":"TC Wu","year":"2013","unstructured":"Wu TC, Yang S, Haven S, Holers VM, Lundberg AS, Wu H, Cataland SR (2013) Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura. J Thromb Haemost 11:1925\u20131927","journal-title":"J Thromb Haemost"},{"key":"3076_CR116","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/bjh.12707","volume":"164","author":"JP Westwood","year":"2014","unstructured":"Westwood JP, Langley K, Heelas E, Machin SJ, Scully M (2014) Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura. Br J Haematol 164:858\u2013856","journal-title":"Br J Haematol"},{"key":"3076_CR117","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.4049\/jimmunol.1301221","volume":"191","author":"R Tati","year":"2013","unstructured":"Tati R, Kristoffersson AC, St\u00e5hl AL, Rebetz J, Wang L, Licht C, Motto D, Karpman D (2013) Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy. J Immunol 191:2184\u20132193","journal-title":"J Immunol"},{"key":"3076_CR118","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1365-2141.2012.09084.x","volume":"157","author":"J Chapin","year":"2012","unstructured":"Chapin J, Weksler B, Magro C, Laurence J (2012) Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol 157:772\u2013774","journal-title":"Br J Haematol"},{"key":"3076_CR119","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/bjh.12387","volume":"162","author":"E Tsai","year":"2013","unstructured":"Tsai E, Chapin J, Laurence JC, Tsai HM (2013) Use of eculizumab in the treatment of a case of refractory, ADAMTS13-deficient thrombotic thrombocytopenic purpura: additional data and clinical follow-up. Br J Haematol 162:558\u2013559","journal-title":"Br J Haematol"},{"key":"3076_CR120","doi-asserted-by":"crossref","first-page":"e1769","DOI":"10.1542\/peds.2013-2921","volume":"133","author":"M Belingheri","year":"2014","unstructured":"Belingheri M, Possenti I, Tel F, Paglialonga F, Testa S, Salardi S, Ardissino G (2014) Cryptic activity of atypical hemolytic uremic syndrome and eculizumab treatment. Pediatrics 133:e1769\u2013e1771","journal-title":"Pediatrics"},{"key":"3076_CR121","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1053\/j.ajkd.2011.11.027","volume":"59","author":"G Ariceta","year":"2012","unstructured":"Ariceta G, Arrizabalaga B, Aguirre M, Morteruel E, Lopez-Trascasa M (2012) Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants. Am J Kidney Dis 59:707\u2013710","journal-title":"Am J Kidney Dis"},{"key":"3076_CR122","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/j.ajkd.2013.09.020","volume":"63","author":"G Ardissino","year":"2013","unstructured":"Ardissino G, Tel F, Testa S, Marzano AV, Lazzari R, Salardi S, Edefonti A (2013) Skin involvement in atypical hemolytic uremic syndrome. Am J Kidney Dis 63:652\u2013655","journal-title":"Am J Kidney Dis"},{"key":"3076_CR123","first-page":"5","volume":"3","author":"M Ohanian","year":"2011","unstructured":"Ohanian M, Cable C, Halka K (2011) Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome. Clin Pharmacol 3:5\u201312","journal-title":"Clin Pharmacol"},{"key":"3076_CR124","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00277-012-1615-y","volume":"92","author":"G Salem","year":"2013","unstructured":"Salem G, Flynn JM, Cataland SR (2013) Profound neurological injury in a patient with atypical hemolytic uremic syndrome. Ann Hematol 92:557\u2013558","journal-title":"Ann Hematol"},{"key":"3076_CR125","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2515\/therapie\/2013017","volume":"68","author":"F Beye","year":"2013","unstructured":"Beye F, Malbranche C, Tramecon D, Pernot C, Zanetta G, Mousson C, Guignard MH, Lazzarotti A (2013) Eculizumab: effectiveness of a shortened dosing schedule in the treatment of atypical haemolytic uremic syndrome of unknown origin. Therapie 68:119\u2013122","journal-title":"Therapie"},{"key":"3076_CR126","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1007\/s00277-013-1972-1","volume":"93","author":"JJ Pu","year":"2014","unstructured":"Pu JJ, Sido A (2014) Successful discontinuation of eculizumab therapy in a patient with aHUS. Ann Hematol 93:1423\u20131425","journal-title":"Ann Hematol"},{"key":"3076_CR127","first-page":"111","volume":"12","author":"P Chaudhary","year":"2014","unstructured":"Chaudhary P, Hepgur M, Sarkissian S, Smith RJ, Weitz IC (2014) Atypical haemolytic-uraemic syndrome due to heterozygous mutations of CFH\/CFHR1-3 and complement factor H 479. Blood Transfus 12:111\u2013113","journal-title":"Blood Transfus"},{"key":"3076_CR128","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1093\/ndt\/gfq319","volume":"25","author":"C Loirat","year":"2010","unstructured":"Loirat C, Macher MA, Elmaleh-Berges M, Kwon T, Desch\u00eanes G, Goodship TH, Majoie C, Davin JC, Blanc R, Savatovsky J, Moret J, Fremeaux-Bacchi V (2010) Non-atheromatous arterial stenoses in atypical haemolytic uraemic syndrome associated with complement dysregulation. Nephrol Dial Transplant 25:3421\u20133425","journal-title":"Nephrol Dial Transplant"},{"key":"3076_CR129","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00467-010-1608-9","volume":"26","author":"JC Davin","year":"2011","unstructured":"Davin JC, Majoie C, Groothoff J, Gracchi V, Bouts A, Goodship TH, Loirat C (2011) Prevention of large-vessel stenoses in atypical hemolytic uremic syndrome associated with complement dysregulation. Pediatr Nephrol 26:155\u2013157","journal-title":"Pediatr Nephrol"},{"key":"3076_CR130","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s00467-013-2713-3","volume":"29","author":"K A\u017eukaitis","year":"2013","unstructured":"A\u017eukaitis K, Loirat C, Malina M, Adomaitien\u0117 I, Jankauskien\u0117 A (2013) Macrovascular involvement in a child with atypical hemolytic uremic syndrome. Pediatr Nephrol 29:1273\u20131277","journal-title":"Pediatr Nephrol"},{"key":"3076_CR131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ckj\/sfs006","volume":"5","author":"M Gargau","year":"2012","unstructured":"Gargau M, Azancot M, Ramos R, Sanchez-Corral P, Montero MA, Seron D (2012) Early treatment with eculizumab may be beneficial in atypical haemolytic uraemic syndrome. Clin Kidney J 5:1\u20133","journal-title":"Clin Kidney J"},{"key":"3076_CR132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.krcp.2011.12.008","volume":"0","author":"JJ Kim","year":"2012","unstructured":"Kim JJ, Simon CW, Reid CJ (2012) Eculizumab in atypical haemolytic-uraemic syndrome allows cessation of plasma exchange and dialysis. Clin Kidney J 0:1\u20133","journal-title":"Clin Kidney J"},{"key":"3076_CR133","first-page":"326","volume":"82","author":"H Povey","year":"2013","unstructured":"Povey H, Vundru R, Junglee N, Jibani M (2013) Renal recovery with eculizumab in atypical hemolytic uremic syndrome following prolonged dialysis. Clin Nephrol 82:326\u2013331","journal-title":"Clin Nephrol"},{"key":"3076_CR134","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/nrneph.2013.280","volume":"10","author":"M Noris","year":"2014","unstructured":"Noris M, Remuzzi G (2014) Cardiovascular complications in atypical haemolytic uraemic syndrome. Nat Rev Nephrol 10:174\u2013180","journal-title":"Nat Rev Nephrol"},{"key":"3076_CR135","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMoa1311084","volume":"370","author":"J Nishimura","year":"2014","unstructured":"Nishimura J, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL, Noji H, Kitamura K, Eto T, Takahashi T, Masuko M, Matsumoto T, Wano Y, Shichishima T, Shibayama H, Hase M, Li L, Johnson K, Lazarowski A, Tamburini P, Inazawa J, Kinoshita T, Kanakura Y (2014) Genetic variants in C5 and poor response to eculizumab. N Engl J Med 370:632\u2013639","journal-title":"N Engl J Med"},{"key":"3076_CR136","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/jth.12615","volume":"12","author":"M Cugno","year":"2014","unstructured":"Cugno M, Gualtierotti R, Possenti I, Testa S, Tel F, Griffini S, Grovetti E, Tedeschi S, Salardi S, Cresseri D, Messa P, Ardissino G (2014) Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost 12:1440\u20131448","journal-title":"J Thromb Haemost"},{"key":"3076_CR137","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2215\/CJN.01090209","volume":"4","author":"CJ Mache","year":"2009","unstructured":"Mache CJ, Acham-Roschitz B, Fr\u00e9meaux-Bacchi V, Kirschfink M, Zipfel PF, Roedl S, Vester U, Ring E (2009) Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 4:1312\u20131316","journal-title":"Clin J Am Soc Nephrol"},{"key":"3076_CR138","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1055\/s-0030-1262889","volume":"36","author":"O K\u00f6se","year":"2010","unstructured":"K\u00f6se O, Zimmerhackl LB, Jungraithmayr T, Mache C, N\u00fcrnberger J (2010) New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab. Semin Thromb Hemost 36:669\u2013672","journal-title":"Semin Thromb Hemost"},{"key":"3076_CR139","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00277-012-1622-z","volume":"92","author":"R Carr","year":"2013","unstructured":"Carr R, Cataland SR (2013) Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation. Ann Hematol 92:845\u2013846","journal-title":"Ann Hematol"},{"key":"3076_CR140","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/ckj\/sfs185","volume":"6","author":"Y Delmas","year":"2013","unstructured":"Delmas Y, Bordes C, Loirat C, Fremeaux-Bacchi V, Combe C (2013) Post-partum atypical haemolytic uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice. Clin Kidney J 6:243\u2013244","journal-title":"Clin Kidney J"},{"key":"3076_CR141","first-page":"1421","volume":"93","author":"C Ca\u00f1igral","year":"2014","unstructured":"Ca\u00f1igral C, Moscard\u00f3 F, Castro C, Pajares A, Lancharro A, Solves P, de la Rubia J, Carpio N, Sanz MA (2014) Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome. Ann Hematol 93:1421\u20131422","journal-title":"Ann Hematol"},{"key":"3076_CR142","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","volume":"64","author":"G Ardissino","year":"2014","unstructured":"Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F, Salardi S, Tedeschi S, Belingheri M, Cugno M (2014) Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis 64:633\u2013637","journal-title":"Am J Kidney Dis"},{"key":"3076_CR143","first-page":"342","volume":"71","author":"JC Verhave","year":"2013","unstructured":"Verhave JC, Westra D, van Hamersvelt HW, van Helden M, van de Kar NC, Wetzels JF (2013) Living kidney transplantation in adult patients with atypical haemolytic uraemic syndrome. Neth J Med 71:342\u2013347","journal-title":"Neth J Med"},{"key":"3076_CR144","doi-asserted-by":"crossref","first-page":"E93","DOI":"10.1111\/petr.12066","volume":"17","author":"TA Forbes","year":"2013","unstructured":"Forbes TA, Bradbury MG, Goodship TH, McKiernan PJ, Milford DV (2013) Changing strategies for organ transplantation in atypical haemolytic uraemic syndrome: a tertiary case series. Pediatr Transplant 17:E93\u2013E99","journal-title":"Pediatr Transplant"},{"key":"3076_CR145","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00467-013-2722-2","volume":"29","author":"J Saland","year":"2014","unstructured":"Saland J (2014) Liver\u2013kidney transplantation to cure atypical HUS: still an option post-eculizumab? Pediatr Nephrol 29:329\u2013332","journal-title":"Pediatr Nephrol"},{"key":"3076_CR146","doi-asserted-by":"crossref","first-page":"481","DOI":"10.4097\/kjae.2014.66.6.481","volume":"66","author":"SH Park","year":"2014","unstructured":"Park SH, Kim GS (2014) Anesthetic management of living donor liver transplantation for complement factor H deficiency hemolytic uremic syndrome: a case report. Korean J Anesthesiol 66:481\u2013485","journal-title":"Korean J Anesthesiol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-015-3076-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-015-3076-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-015-3076-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T15:42:32Z","timestamp":1651678952000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-015-3076-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,11]]},"references-count":146,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["3076"],"URL":"https:\/\/doi.org\/10.1007\/s00467-015-3076-8","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,11]]}}}